UBS upgrades Regeneron stock to Buy with USD 978 target

Published on 10/16/2026 at 10:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock stands at EUR 710.40 on October 16, 2026. Revenue rose to USD 4.29 billion, up 16.70 percent, before scheduled October 30 results.

Analyst target and reporting date

UBS moved its Regeneron rating from Neutral to Buy and set a USD 978.00 target on October 15, 2026.
Second-quarter revenue reached USD 4.29 billion, up 16.70 percent year over year.
Regeneron stock stood at EUR 710.40 at 10:40 a.m. CEST at Lang & Schwarz on October 16, 2026.
Third-quarter results are scheduled for October 30, 2026.

Flatlay mit Aktienzertifikat, ISIN-Karte, Pipette und Laborutensilien von oben fotografiert — Regeneron Pharma US75886F1075 kombiniert in einem Flatlay Aktienzertifikat, ISIN-Karte, Pipette sowie kleine Antikörper-Fläschchen übersichtlich, Illustration mit AI erstellt.

Regeneron Pharmaceuticals (ISIN US75886F1075) received a fresh analyst upgrade as UBS moved the rating from Neutral to Buy and raised its price target from USD 660.00 to USD 978.00 on October 15, 2026, according to MarketBeat. The move puts the analyst view well above the company's recent market valuation and keeps Dupixent at the center of the investment case.

UBS points to Dupixent

UBS linked its upgrade to the long-term growth opportunity for Dupixent, Regeneron's immunology medicine marketed with Sanofi, as reported by MarketBeat. The report also showed a broad analyst consensus of Moderate Buy and an average target of USD 845.21, although those figures represent an aggregate view rather than UBS's individual target.

The latest reported operating figures support the debate over future earnings power. Regeneron generated USD 4.29 billion in revenue in the second quarter of 2026, up 16.70 percent from the prior-year quarter, while earnings per share reached USD 14.29 against a USD 10.16 consensus estimate, according to MarketBeat. Revenue therefore exceeded the cited consensus of USD 3.82 billion by USD 470.00 million.

What comes next for results?

Regeneron has scheduled its third-quarter 2026 financial and operating results for October 30, 2026, before the U.S. financial markets open. The company will hold its conference call at 8:30 a.m. ET, according to the Regeneron release. That date gives investors a clear test for whether the second-quarter growth rate and the Dupixent thesis are carrying into the second half.

Stock price and valuation

Regeneron is listed on the Nasdaq under ticker REGN. Its market capitalization was USD 81.99 billion and its 52-week range was USD 564.00 to USD 859.34 as of October 15, 2026, according to the cited market data. The current euro quotation places the stock below the upper end of that U.S. dollar range, but the currencies are not directly comparable.

Regeneron stock was trading at EUR 710.40 at Lang & Schwarz on October 16, 2026 at 10:40 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.